ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker

Reuters10-03

ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker

ALX Oncology Holdings Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2572500108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572500108","market":"us","top_or_hot":-1,"title":"ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-03 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALXO","symbol_name":"ALX Oncology Holdings","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL3cVSyG:1","article_id":"2572500108","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572500108","pubTimestamp":1759496718,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker. ALX Oncology Holdings Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer  40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN , CYRAMZA , and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALXO":"ALX Oncology Holdings","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"ALX Oncology宣布Evorpacept治疗HER2+胃癌的积极2期试验结果，强调CD47是预测性生物标志物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXO":0.9,"NDAQ":0.9},"content_text":"ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n    \n\nALX Oncology Holdings Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572500108","isCrawlerRequest":true}